NCT02180464View on ClinicalTrials.gov

A Intra-individual Comparison to Investigate the Efficacy and the Safety of LAS41004 Formulation in Mild to Moderate Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Psoriasis
Interventions
DRUG

LAS41004

DRUG

control

Trial Locations (1)

Unknown

Site 1, Hamburg

Sponsors

Lead Sponsor

Almirall, S.A.
All Listed Sponsors
lead

Almirall, S.A.

INDUSTRY